EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel By Ogkologos - August 26, 2025 201 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Remote Monitoring of Patients Treated with Oral Anticancer Drugs Improves Patient... May 11, 2022 New study to detect oesophageal cancer earlier April 28, 2022 Woman Perfectly Breaks Down Grief Using ‘Ball In The Box’ Analogy... March 8, 2019 Latest episode of our podcast for cancer researchers March 23, 2022 Load more HOT NEWS A toolkit to address disparities in digitally enabled oncology trials New option to treat advanced oesophageal cancer approved for NHS in... Here’s Why We’re Building Pet-Friendly Domestic Violence Shelters–And How You Can... FDA Approves Lutetium Lu 177 Dotatate for Paediatric Patients 12 Years...
